pbm outlook receiv view primari driver ci strong stock
perform thur vs peer bp
increas confid underli growth trajectori health servic
pbm segment lesser degre out-performance integr
medic segment drill deeper pbm result quarterli pbm bridg
figur walk three discret item impact earn legaci
contract strand overhead cost annual suppli chain initi
increment deal synergi per schedul said think midpoint
segment guidanc mn impli underli core growth repres
meaning acceler core growth seen
ep guidanc ci expect ep repres growth
adjust ep baselin touch previou
growth commentari driven calendar year hif headwind
stem mid-year renew commerci busi importantli ci ep
guidanc typic lean conserv given reflect impact futur
share repurchas favor develop note ci outperform
initi guidanc midpoint
reiter ow follow today result trim ep estim
reflect hif headwind leav ep estim intact ci
current trade ntm ep impli multipl pbm busi
rang given eas concern around pbm busi model coupl
attract growth acceler prime partnership think ci multipl
could re-rat higher maintain ow rate pt price-to-earnings
ep
ci quarterli annual ep usd
return equiti ttm
idc link barclay live interact chart
consensu number bloomberg receiv gmt
barclay capit inc and/or one affili seek busi
compani cover research report result investor awar
firm may conflict interest could affect object report investor
consid report singl factor make invest decis
margin return data
overweight continu leverag
strength control medic cost continu
gain market share commerci busi
return industri growth medicar
upsid case reflect favor medic
cost trend outlook higher expect share
gain commerci medicar segment
downsid case reflect risk associ
increas cost trend aggress commerci price
lower expect commerci growth
balanc sheet cash flow mn
equival
short long-term debt
chang work capit
flow oper
valuat leverag metric
pbm commentari earn call
health servic busi expect full year earn rang billion billion
repres year-over-year growth rang health servic expect first quarter earn
grow mid-singl digit percentag first quarter outlook reflect solid underli growth benefit
increas year-over-year administr expens synergi would also note expect first quarter
servic sg expens ratio higher first quarter reflect impact client transit discuss
previous includ start-up cost associ collabor prime cfo eric palmer
pre-tax strand overhead front-end annual suppli chain initi assum increment synergi mn mn growth impli pre-tax y/i pre-tax incom strandedoverheadannu supplychain initiativesincrementalsynergi growth pre-tax incomeguid barclay
initi guidanceconsolid oper metricsadjust revenu adjust incom oper adjust sg expens adjust tax interest adjust margin debt capit segment oper metricshealth servic pre-tax incom adjust pharmaci billion integr medic pre-tax incom medic medic global medic custom medicar total global medic custom barclay
 consolid incom statement pharmaci invest adjust changetot expensesmed benefit medic servic excl intang oper incom loss attribut includ margin expens adjust margin tax net incom margin share fulli barclay
health servic segment pharmaci invest servic oper loss attribut expens adjust margin medic invest oper loss attribut adjust margin assumptionsfe revenenu loss subject py sg barclay
steve valiquett herebi certifi view express research report accur reflect person view
subject secur issuer refer research report part compens directli indirectli relat
specif recommend view express research report
barclay research produc invest bank barclay bank plc affili collect individu barclay
author contribut research report research analyst unless otherwis indic public date top report
reflect local time report produc may differ releas date provid gmt
avail disclosur
compani subject research report current import disclosur regard compani pleas refer
http //publicresearch barclay com altern send written request barclay research complianc seventh avenu floor
new york ny call
analyst respons prepar research report receiv compens base upon variou factor includ firm total
revenu portion gener invest bank activ profit revenu market busi
potenti interest firm invest client research respect asset class cover analyst
analyst regularli conduct site visit view materi oper cover compani barclay polici prohibit accept
payment reimburs cover compani travel expens visit
barclay research depart produc variou type research includ limit fundament analysi equity-link analysi
quantit analysi trade idea recommend contain one type barclay research may differ contain
type barclay research whether result differ time horizon methodolog otherwis
http //publicresearch barcap com/s/rd htm order access barclay research conflict manag polici statement pleas refer
procedur pleas
unless otherwis indic price sourc bloomberg reflect close price relev trade market may
last avail price time public
